AzTrials
AzTrials

Diabetes Mellitus, Type 1CODECNCT02973412

Chronotype of Patients With Diabetes and Effect on Glycaemic Control

An observational study of Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, run by University of Leicester at 1 site in United Kingdom.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study is to explore the associations between chronotype and glycaemic control, cardiometabolic health and other lifestyle factors. Read more about this study

Who is it for?
Ages 18 to 75 years
How many people
3,447 participants
Where
1 siteUnited Kingdom
Study dates
7 Dec 2016to 31 Dec 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Participants with established (>6months since diagnosis) T1DM or T2DM, between the age of 18-75 years inclusive, who do not currently have a known sleep disorder (excluding OSA).

Who may be able to join

  • Participant is willing and able to give informed consent for participation in the study
  • T1DM or established T2DM (>6months since diagnosis)
  • Male or Female
  • Aged 18-75 years inclusive
  • BMI less than or equal to 45kg/m² inclusive
  • No known sleep disorders except Obstructive Sleep Apnoea (OSA)
  • On any glucose-lowering therapy (T1DM or T2DM) or lifestyle modification for management of T2DM
  • Good command of the English language

Who cannot join

  • Participant is unwilling or unable to give informed consent
  • Anyone without a good command of the English language
  • Anyone <18 years of age and >75 years of age
  • BMI greater than 45 kg/m²
  • A regular cannabis user i.e. weekly use
  • Have a terminal illness
  • A known sleep disorder that is not OSA
  • Regular use of the following medicines i.e. Weekly use: (Wakefulness promoting agents Modafinil, Amphetamine derivatives, Methylphenidate; Sedatives including benzodiazepines, Z-drugs (zopiclone, zolpidem \& zaleplon); Melatonin, including Circadin and melatonin analogues; Clonazepam and other drugs for nocturnal movement disorders).

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

United Kingdom1 site, 1 recruiting
  • Leicester Diabetes Centre, Leicester General Hospital

    Leicester, LE5 4PW

    Sahar Khodabakhsh, PhD, 0116 258 8070, sahar.khodabakhsh@uhl-tr.nhs.uk

    Recruiting

Other trials in United Kingdom

About this study

Official title: Chronotype of Patients With Diabetes and Effect on Glycaemic Control: The CODEC Study

The aim of this study is to explore the associations between chronotype and glycaemic control, cardiometabolic health and other lifestyle factors.

Read the detailed description

The incidence and prevalence of diabetes mellitus has now reached over 5 million in the United Kingdom (UK). Type 2 diabetes mellitus (T2DM) accounts for approximately 90% of the UK population with diabetes and is a condition characterised by hyperglycaemia, resulting from defects in hepatic and peripheral glucose uptake, insulin secretion, or both. Conversely, around 8% of those diagnosed with diabetes, have Type 1 diabetes mellitus (T1DM). This equates to ~400,000 people in the UK. The incidence of new diagnoses of T1DM is also increasing by about 4% each year, with around half of these being in people over the age of 18. T1DM is caused by an autoimmune reaction where the body's defence system attacks the cells that produce insulin. As such, T1DM requires life-long treatment with exogenous insulin therapy accompanied by blood glucose monitoring.

Regardless of type, there is an increased vulnerability to microvascular (nephropathy, neuropathy, and retinopathy) and macrovascular complications (coronary artery disease, peripheral arterial disease, and stroke). As a result, new paradigms for characterising and treating these patients could enhance current and future diabetes management.

Recently, there has been considerable interest in the association between quantity and quality of sleep and circadian rhythms and the development and management of cardiometabolic disease especially metabolic syndrome, diabetes and Cardiovascular Disease (CVD). A "U"-shaped relationship related to both short and long sleep duration exists between sleep duration and diabetes, obesity, CVD, hypertension and stroke. A meta-analysis of nearly 500,000 individuals (~4% T2DM) identified a relative risk (RR) of 1.14 (95% CI 1.03-1.26) for every additional hour of sleep and RR 1.09 (95% CI 1.04-1.15) with each hour of shorter sleep compared to 7-hours sleep per day for the development of T2DM. Despite this many individuals do not consider sleep essential for good health but instead consider it to be rather more of an inconvenience. Subsequently, lifestyle choices, societal pressures and shift-work render the population chronically sleep deprived and thus at increased risk of metabolic dysfunction.

Sleep is regulated, in part, by a homeostatic drive and is therefore unavoidable in humans (without sleep disorders). The circadian system, our internal clock, is also responsible for the regulation of sleep. Sleep is a multidimensional behaviour (and biological process) where we need to not only consider duration and quality but timing also. A person's sleep pattern, in relation to the 24-hour clock, i.e. timing, is individual to them and referred to as their chronotype. We can quantitatively characterise these individual differences in daily timing using a number of questionnaire based tools.

Five different chronotypes have been identified using the 'Morningness-Eveningness' Questionnaire i.e. definite evening type, moderate evening type, intermediate, moderate morning type and definite morning type. The identification of these different chronotypes, which describes preferred circadian phases, into, at the two extremes, "morning type" and "evening type" has led to further research confirming that "evening types" are at greater risk of cardiometabolic disease and metabolic dysfunction. The underlying causes have not been clearly defined but appear to be related to circadian mal-alignment causing chronic sleep deprivation and leading to dysregulation of metabolic, immune and hormonal processes that govern energy regulation and glycaemic control.

Several clock genes have been identified in the control of circadian rhythms including Clock (Circadian locomotor output cycles protein kaput), Npas2 (Neuronal PAS domain protein2), Bmal1 (Brain and muscle ARNT-like protein), Per1 (Period), Per2, Per3, Cry1 (Cryptochrome), Cry2, Rev-Erbs (Reverse erythroblastosis virus) and CkI (Casein kinase). However their role if any, in progression in diabetes remains to be elucidated.

The concept of "social jetlag" has been developed to describe the deleterious effects of chronic sleep deprivation related to weekday occupational obligations on "evening types" and weekend social demands on "morning types". For example, a large epidemiological study in Germany has shown that social jetlag is associated with obesity. Several public health questions are raised by these associations, not least whether chronotyping of all individuals should be considered and whether the individual chronotype can be adjusted by sleep hygiene and training (which requires discipline for maintenance) and/or exogenous treatment with melatonin.

In this cross-sectional observational study, we therefore propose to extensively chronotype a sample of patients with T1DM and T2DM to determine the impact of chronotype on glycaemic control, insulin resistance, biochemical profile, and inflammatory, adipocytokine and genetic markers using a validated questionnaire and blood tests.

In an optional sub-study, we will explore the association between diabetes, chronotype and objectively measured physical activity, energy intake, clock genes and well-being. We will also offer participants the opportunity to wear a continuous glucose monitor. Those that have consented to take part in the optional sub-study, and to be contacted about future ethically approved research, will also be offered the opportunity to have these measurements repeated at a later date.

Medical subject headings
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. HBA1C level (%) measured from a blood sample

    Measured: Baseline (1 time point)

Secondary outcomes (35)
  1. Mid-Sleep Time (MSF) - on both free and work days

    Measured: Baseline (1 time point)

  2. Glucose (mmol/L)

    Measured: Baseline (1 time point)

  3. Insulin (mmol/L)

    Measured: Baseline (1 time point)

  4. C-Peptide (ng/mL (conventional units), or nmol/L (SI))

    Measured: Baseline (1 time point)

  5. Total cholesterol levels (mmol/L)

    Measured: Baseline (1 time point)

  6. HDL-cholesterol levels (mmol/L)

    Measured: Baseline (1 time point)

  7. LDL-cholesterol levels (mmol/L)

    Measured: Baseline (1 time point)

  8. Triglyceride levels (mmol/L)

    Measured: Baseline (1 time point)

  9. Liver function test (including AST, ALT, ALP and albumin)

    Measured: Baseline (1 time point)

  10. Weight (Kg)

    Measured: Baseline (1 time point)

  11. Body composition via bioimpedance

    Measured: Baseline (1 time point)

  12. Height (cm)

    Measured: Baseline (1 time point)

  13. Blood pressure (mmHg)

    Measured: Baseline (1 time point)

  14. hsCRP (mg/L)

    Biomarker of inflammation

    Measured: Baseline (1 time point)

  15. Levels of physical activity (Recall Physical Activity Questionnaire,RPAQ)

    Measured: Baseline (1 time point)

  16. Duration of diabetes

    Measured: Baseline (1 time point)

  17. Consumption of Pathogen Associated Molecular Patterns (PAMPs)

    Measured: Baseline (1 time point)

  18. Sleep duration (self-report)

    Measured: Baseline (1 time point)

  19. Physical function (self - report)

    Measured: Baseline (1 time point)

  20. Physical performance (Short Physical Performance Battery (SPPB) plus hand grip)

    Measured: Baseline (1 time point)

  21. Objective measures of physical activity and sleep duration (GENEActiv)

    Measured: Baseline (1 time point)

  22. Energy intake (24-hour dietary recall (DR))

    Measured: Baseline (1 time point)

  23. Clock genes (whole blood sample)

    Measured: Baseline (1 time point)

  24. Temporal distribution of calorie intake (determined by 24-hr food recall)

    Measured: Baseline (1 time point)

  25. Prevalence of each chronotype category

    Measured: Baseline (1 time point)

  26. IL-6 (pg/ml)

    Biomarker of inflammation

    Measured: Baseline (1 time point)

  27. Leptin (ng/L)

    Biomarker of inflammation

    Measured: Baseline (1 time point)

  28. Adiponectin (pg/ml)

    Biomarker of inflammation

    Measured: Baseline (1 time point)

  29. Age of onset

    Age at which the participant was diagnosed with Type 2 Diabetes

    Measured: Baseline (1 time point)

  30. Symptoms of depressive disorder (PHQ-9)

    Measured: Baseline (1 time point)

  31. Level of diabetes specific distress (DDS-17)

    Measured: Baseline (1 time point)

  32. Level of self-compassion (SCS)

    Measured: Baseline (1 time point)

  33. The Hypoglycaemic Confidence Scale (HCS)

    Measured: Baseline (1 time point)

  34. Gold Score

    Measured: Baseline (1 time point)

  35. Continuous Glucose Monitoring (CGM)

    Measured: Baseline (1 time point)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Nov 2016 (estimated)
  2. Study start7 Dec 2016
  3. Primary completion31 Dec 2027 (estimated)
  4. Study completion31 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case only
Time perspective
Cross-sectional
Enrolment
3,447 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02973412
Sponsor's protocol ID
0590
Acronym
CODEC
Status last verified
Feb 2024
First submitted
26 Oct 2016
Last updated
15 Feb 2024
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Publications

  • Gunn S, Henson J, Robertson N, Maltby J, Brady EM, Henderson S, Hadjiconstantinou M, Hall AP, Rowlands AV, Yates T, Davies MJ. Self-compassion, sleep quality and psychological well-being in type 2 diabetes: a cross-sectional study. BMJ Open Diabetes Res Care. 2022 Sep;10(5):e002927. doi: 10.1136/bmjdrc-2022-002927.

    PubMed 36171016
  • Henson J, Rowlands AV, Baldry E, Brady EM, Davies MJ, Edwardson CL, Yates T, Hall AP; CODEC Investigators. Physical behaviors and chronotype in people with type 2 diabetes. BMJ Open Diabetes Res Care. 2020 Jul;8(1):e001375. doi: 10.1136/bmjdrc-2020-001375.

    PubMed 32675292
  • Brady EM, Hall AP, Baldry E, Chatterjee S, Daniels LJ, Edwardson C, Khunti K, Patel MI, Henson JJ, Rowlands A, Smith AC, Yates T, Davies MJ. Rationale and design of a cross-sectional study to investigate and describe the chronotype of patients with type 2 diabetes and the effect on glycaemic control: the CODEC study. BMJ Open. 2019 Nov 11;9(11):e027773. doi: 10.1136/bmjopen-2018-027773.

    PubMed 31719069

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, run by University of Leicester at 1 site in United Kingdom.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 15 Feb 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United Kingdom. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Sahar Khodabakhsh, PhD (0116258 ext. 8070, sahar.khodabakhsh@uhl-tr.nhs.uk), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

HBA1C level (%) measured from a blood sample (time frame: Baseline (1 time point)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02973412, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Feb 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in